

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date April 15, 2011

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

DRAFT

Call to Order – Chair Richard Brodsky, MD

8:00 am

Roll Call

8:05 am

Public Comment - (See guidelines on page 2)

Local Public / Health Practitioners

The Department has developed a new method for class review to better utilize the time of the P&T Committee. Three sets of classes are up for review. Classes shown in **Red** are new classes or classes where new information exists and public testimony will be taken. Classes shown in **Blue** will be reviewed only if new information is received, then public testimony will be taken. For the classes shown in **Green**, no changes have been noted and no public testimony will be taken. New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

Public Comment on Blue/Red Classes	
Discussion & vote on Red Classes	
The Department will review the following red classes as the classes are new or new information exists.	
*Review Ophthalmic Macrolides	*Review Self Injectable Epinephrine
*Review Anti-viral - Influenza	
The Department proposes no changes to the P&T Committee's clinical recommendation in the following blue classes unless new information is received.	
Re-Review Ophthalmic Quinolones	Re-Review Intranasal Antihistamines
Re-Review Nasal Steroids	Re-Review Ophthalmic NSAIDS
Re-Review Ophthalmic Anti-Allergy Agents	Re-Review Anti-Migraines
Re-Review Anti-Emetics	Re-Review Inhaled Steroids
Re-Review Leukotriene Inhibitors	Re-Review Anti-Herpes Oral Medication
Re-Review Topical Antivirals	Re-Review Hepatitis B - Oral
The Department proposes no changes to the P&T Committee's clinical recommendation to the following classes as shown in green .	
Re-Review Ophthalmic Mast Cell Stabilizers	Re-Review Otic Quinolones
Re-Review 2nd & 3rd Generation Quinolones	Re-Review 2nd & 3rd Generation Cephalosporins
Re-Review Macrolides	Re-Review Long Acting Beta Agonists
Re-Review Short Acting Beta Agonists	Re-Review COPD Inhalant Drugs
Re-Review Ophthalmic Immunomodulator	Re-Review Hepatitis C
Re-Review Anti-Fungal - Onychomycosis	Re-Review Topical Antibiotics
Re-Review Topical Antifungals	
Break as needed – 15 minutes -	
Review minutes from January 2011 meeting	
Comments from Committee Members or Chair	
Adjourn	

Tentative Future Meeting Dates: September 16, 2011, November 18, 2011, January 20, 2012
& April 20, 2012

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE
April 15, 2011

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.